Co-Authors
This is a "connection" page, showing publications co-authored by KAREN HOFFMAN and BRIAN FRANCIS CHAPIN.
Connection Strength
0.740
-
Radical prostatectomy or radiotherapy for high- and very high-risk prostate cancer: a multidisciplinary prostate cancer clinic experience of patients eligible for either treatment. BJU Int. 2019 11; 124(5):811-819.
Score: 0.173
-
Discerning the survival advantage among patients with prostate cancer who undergo radical prostatectomy or radiotherapy: The limitations of cancer registry data. Cancer. 2017 05 01; 123(9):1617-1624.
Score: 0.147
-
Proton therapy toxicity outcomes for localized prostate cancer: Long-term results at a comprehensive cancer center. Clin Transl Radiat Oncol. 2024 Sep; 48:100822.
Score: 0.062
-
Definitive local therapy for T4 prostate cancer associated with improved local control and survival. BJU Int. 2023 09; 132(3):307-313.
Score: 0.057
-
Influence of Geography on Prostate Cancer Treatment. Int J Radiat Oncol Biol Phys. 2021 04 01; 109(5):1286-1295.
Score: 0.048
-
Increased Frequency of Mesorectal and Perirectal LN Involvement in T4 Prostate Cancers. Int J Radiat Oncol Biol Phys. 2020 08 01; 107(5):982-985.
Score: 0.046
-
Costs and Complications After a Diagnosis of Prostate Cancer Treated With Time-Efficient Modalities: An Analysis of National Medicare Data. Pract Radiat Oncol. 2020 Jul - Aug; 10(4):282-292.
Score: 0.046
-
Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer. JAMA Netw Open. 2020 03 02; 3(3):e201255.
Score: 0.046
-
Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. Cancer. 2020 02 01; 126(3):506-514.
Score: 0.045
-
Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU Int. 2018 04; 121(4):540-548.
Score: 0.039
-
Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016 07; 118(1):68-76.
Score: 0.033